Business Context and Reporting Period
Company: Butterfly Network, Inc. (BFLY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Butterfly Network is a digital health company developing portable, semiconductor-based ultrasound technology ("Ultrasound-on-Chip"). The company sells handheld ultrasound devices (Butterfly iQ+ and iQ3), software subscriptions, and professional services to healthcare systems, physicians, and veterinarians globally. The company operates as a single reportable segment.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Total Revenue | $82.1 | $65.9 |
| Product Revenue | $54.2 | $40.0 |
| Software & Services Revenue | $27.9 | $25.9 |
| Gross Profit | $48.8 | $16.9 |
| Gross Margin | 59.5% | 25.6% |
| Net Loss | $(72.5) | $(133.7) |
| Operating Loss | $(74.4) | $(145.6) |
| Cash & Cash Equivalents (Dec 31, 2024) | $88.8 | $134.4 |
| Accumulated Deficit (Dec 31, 2024) | $(802.1) | $(729.6) |
Liquidity: As of December 31, 2024, the company held $88.8 million in cash and cash equivalents. On January 31, 2025, the company raised an additional $86.9 million in gross proceeds through a public offering of 27.6 million shares of Class A common stock.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24.5% year-over-year, driven primarily by a 35.4% increase in product revenue. This growth was fueled by the launch of the next-generation Butterfly iQ3 probe and higher volume across U.S. sales channels.
- Margin Expansion: Gross margin improved significantly from 25.6% in 2023 to 59.5% in 2024. This improvement was largely due to the non-recurrence of a $21.1 million inventory write-down recorded in 2023.
- Expense Reduction: Operating expenses decreased by approximately $39.2 million year-over-year. Research and Development (R&D) expenses dropped 32.0% due to workforce optimization and business transformation initiatives. General and Administrative (G&A) expenses fell 19.8%.
- Loss Reduction: Net loss narrowed by 45.8% to $72.5 million, reflecting both revenue growth and significant cost containment measures.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management continues to focus on commercializing the iQ3 probe, expanding enterprise software adoption, and optimizing resources. The company expects to continue investing in growth while maintaining a focus on cash preservation. A new "HomeCare Services Business" was introduced in March 2024, with a pilot program for virtual chronic care management initiated in January 2025.
Risks and Contingencies:
- Profitability: The company has incurred losses since inception and anticipates continuing to incur significant losses for at least the next several years.
- Supply Chain Concentration: The company relies on a single supplier (TSMC) for semiconductor chips and a single contract manufacturer (Benchmark Electronics) for assembly. Disruptions in these relationships could materially harm operations.
- Legal Proceedings: The company is subject to a securities class action lawsuit and stockholder derivative actions filed in 2022 regarding the Business Combination. The outcome is uncertain and could have a material adverse effect.
- Regulatory: Products are subject to extensive FDA and international regulations. Failure to maintain compliance or obtain necessary clearances could restrict sales.
Unusual Items: The 2023 financial results were significantly impacted by a $21.1 million loss on excess inventory, which did not recur in 2024. Additionally, "Other" operating expenses in 2023 included $18.2 million related to severance and legal costs, compared to $4.1 million in 2024.
Key Facts for Investor Verification
- Cash Runway: Verify the impact of the January 2025 capital raise ($86.9M gross) on the company's liquidity and ability to fund operations given the $802.1M accumulated deficit.
- Inventory Valuation: Confirm the methodology for inventory valuation and the absence of significant write-downs in 2024 compared to the $21.1M charge in 2023.
- Supplier Dependency: Assess the risks associated with reliance on TSMC (Taiwan) and Benchmark Electronics (Thailand) for critical components and manufacturing.
- Software Mix: Monitor the "Software and other services mix," which decreased to 33.9% in 2024 from 39.2% in 2023, as the company shifts focus to higher-margin recurring revenue.
- Legal Exposure: Track the status of the ongoing securities class action and derivative lawsuits regarding the 2021 Business Combination.